Society for Immunotherapy of Cancer (SITC)
Terri Holzen is a seasoned professional in the field of scientific affairs and education, currently serving as the Scientific Affairs & Education Manager for the Society for Immunotherapy of Cancer (SITC) since November 2021. Prior to this role, Holzen was the Grants Manager at the Hemostasis and Thrombosis Research Society Inc from March 2019 to December 2021. Holzen's academic career includes positions as Associate Professor and Assistant Professor at Mount Mary University and Colorado College, respectively, with expertise in teaching undergraduate courses in genetics, molecular/cellular biology, and microbiology. Additionally, Holzen held the role of Postdoctoral Fellow at the University of Colorado Denver and worked as an Adjunct Instructor at Regis University. Holzen holds a Ph.D. in Genetics from the University of Chicago and a Bachelor of Science in Biology from Indiana University Bloomington.
This person is not in the org chart
This person is not in any teams
Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.